Meng Hui, Gao Xianzheng, Zhang Lan, Liu Fang, Li Wencai
Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Pfizer Oncology Medical Affairs, Chengdu 610041, China.
Zhongguo Fei Ai Za Zhi. 2015 Feb;18(2):75-9. doi: 10.3779/j.issn.1009-3419.2015.02.04.
Besides epidermal growth factor receptor (EGFR) mutation, the non-small cell lung cancer (NSCLC) of anaplastic lymphoma kinase (ALK) rearrangement becomes another important clinical subtype. A specific and high-sensitive and economical detection way is convenience for identification of ALK positive NSCLC quickly and accurately. So the objective of our research is to detect ALK rearrangement in 172 cases of NSCLC by using enhancing immunohistochemical way (ventana-IHC, V-IHC).
ALK rearrangement in 172 NSCLC samples was detected by using V-IHC, and positive staining cases were further verified by fluorescence in situ hybridization (FISH).
Among 172 NSCLC cases, there were 12 positive staining. The positive results were confirmed by FISH and 11 cases were FISH positive. The overall concordance between V-IHC and FISH is 91.7% (11/12).
The V-IHC method is a reliable method for ALK arrangement and could be used in clinical screen and diagnosis.
除表皮生长因子受体（EGFR）突变外，间变性淋巴瘤激酶（ALK）重排的非小细胞肺癌（NSCLC）成为另一种重要的临床亚型。一种特异、高灵敏且经济的检测方法便于快速、准确地鉴定ALK阳性NSCLC。因此，我们研究的目的是采用增强免疫组化方法（ventana免疫组化，V-IHC）检测172例NSCLC中的ALK重排。
采用V-IHC检测172例NSCLC样本中的ALK重排，对阳性染色病例进一步用荧光原位杂交（FISH）验证。
172例NSCLC病例中，有12例阳性染色。FISH证实了阳性结果，11例FISH阳性。V-IHC与FISH的总体一致性为91.7%（11/12）。
V-IHC方法是检测ALK重排的可靠方法，可用于临床筛查和诊断。
Zotero 插件